Cardiovascular Disease Management in HIV Infection

Transcription

1 Slide 1 of XX Cardiovascular Disease Management in HIV Infection Turner Overton, MD Professor of Medicine University of Alabama at Birmingham Birmingham, Alabama Learning Objectives After attending this presentation, learners will be able to: Describe changing epidemiology of CVD in HIV Identify risk factors for CVD in HIV Develop patient-centered strategies to prevent CVD Slide 3 of XX Population All Patients seen in last 12 months Recorded CD4 in last 6 months Expanding 1917 Clinic Population ART Utilization And Viral Suppression 2012 Apr Jul (82%) # Receiving ART 1807 (92%) HIV VL < 1000 cp/ml 1668 (92%) 2126 (86%) 2316 (93%) 2108 (91%) 2469 (86%) 2599 (90%) 2313 (89%) 2270 (73%) 2963 (96%) 2661 (90%) 2125 (66%) 3020 (94%) 2773 (92%) HIV VL < 200 cp/ml 2642 (87%) HIV VL < 50 cp/ml 1347 (75%) QM Metrics: ART 1. >85% on ART 2. >85% on ART VL < 1000cp/mL 3. >80% on ART VL < 50cp/mL 1781 (77%) 2036 (78%) 2397 (81%) 2504 (83%) 2145 (65%) 3151 (96%) 2880 (91%) 2762 (88%) 2558 (81%) 2508 (76%) 3181 (96%) 2925 (92%) 2826 (89%) 2665 (83%) 2331 (69%) 3277 (97%) 3021 (92%) 2907 (89%) 2768 (81%) 134 not receiving ART 79 pts with CD4> pts with CD pts with CD4 <200 Jul (73%) 3332 (96%) 3089 (93%) 2991 (90%) 2670 (83%)

2 Trends In Presenting CD4 Counts 353 c/mm 3 CD4 counts at clinic entry are increasing! Case A 45 yo white male presents for care. He smokes and had a BMI of 24.5 kg/m 2. BP is 145/86. He does not exercise. CD4 count is 325 c/mm3 (16%) Plasma HIV RNA of 42,000 cp/ml. Total cholesterol is 196 mg/dl, LDL 125 mg/dl, HDL 25 mg/dl, TG 175mg/dL. What is the most important intervention to reduce cardiovascular disease risk? ARS Question: What is the most important intervention to reduce cardiovascular disease risk? 1. Smoking cessation 2. Initiate Mediterranean Diet 3. Initiate statin 4. Initiate daily aspirin 5. Initiate ART

3 CVD Mortality Higher in HIV-positive, even with Suppressed HIV Virus. 145,009 HIV+ subjects % male, median age 49 yrs CVD mortality 54% increase (7 13%) Decreasing in gen population ahr 1.54 (95% CI: ) Adjusted for age, sex, race/ethnicity, location, and year Rate if VL > 400cp/mL: 7.7/1000pt yr Rate if VL suppressed: 3.9/1000pt yr General population: 3.2/1000pt yr HIV-related CV and Cancer-related Hanna et al. Clin Infect Dis. 2016;63(8): Freiberg et al. JAMA Intern Med Apr 22;173(8): Lifespan increased but increased burden of CVD fold increased risk Impact of HIV on risk comparable to traditional risk factors including HTN, DM and hyperlipidemia. Increased risk for Myocardial infarction Ischemic stroke Heart failure Pulmonary Hypertension Venous thrombosis Risk Factor Contribution to CVD Hsue and Waters. Circulation. 2018;38: Increasing Burden of CVD among Adult PWH Males Aged >25 years 4.9% Females Aged >25 years 3.8% 2.1% 1.9% Feinstein MJ et al. American Journal of Cardiology; 2016, 117:

4 Interplay between Traditional Risk Factors HIV-specific Risk Factors (Immune activation/inflammation) ART-related toxicities Increased CVD Risk is Multifactorial Certain behaviors (i.e. smoking) Disparities in access/receipt of care Önen and Overton. Current Aging Science : Many pathogenic stimuli induce a similar inflammatory response. Interleukins Tumor Necrosis Factor TGF-beta With removal of the stimulus Inflammation decreases Healing occurs When the stimulus persists Pathogenic responses occur Fibrosis Tissue destruction Altered function Progressive Disease The Inflammation Hypothesis Forrester and Libby. American Journal of Cardiology; 2007, 5: Many pathogenic stimuli induce a similar inflammatory response. Interleukins Tumor Necrosis Factor TGF-beta With removal of the stimulus Inflammation decreases Healing occurs The Inflammation Hypothesis When the stimulus persists Pathogenic responses occur Fibrosis Tissue destruction Altered function Progressive Disease HIV INFECTION END ORGAN DISEASE Forrester and Libby. American Journal of Cardiology; 2007, 5:

5 Residual CV Disease Risk With Suppressed Viremia Vascular inflammation is greater with HIV infection Increased metabolically active macrophages Greater non-calcified, metabolically active, rupture-prone plaque Low Attenuation Plaque Positively Remodeled Plaque Spotty Calcified Plaque Yarasheski et al. J Inflammation Zanni M. AIDS. 2013; 27: Potential Interventions Beyond Suppressive ART Smoking cessation Key lifestyle factors Diet Exercise ART Switch Lipid lowering therapy, aka statins Address other traditional factors HTN DM/Insulin resistance ARS Question: In a suppressed patient with a history of MI, which statement about statin use is accurate? 1. Persons on ART should avoid statin therapy given overlapping toxicity. 2. Simvastatin is the preferred statin for persons on ART. 3. Statin dosing is the same for persons with HIV as the general population. 4. HIV protease inhibitors interact with some statins and increase the risk of statin-related adverse events. 5. In HIV, statin therapy is used to raise HDL since LDL is not a reliable measure in the setting of HIV infection.

6 Statins Reverse Atherosclerosis! Atorvastatin: Reduction in Coronary Artery Plaque Volume by coronary CT angiography (CCTA). Coronary plaque in 53% of the HIV group (also rupture-prone noncalcified plaque) 35% of the HIV-negative group Regression with Atorvastatin beyond expected with LDL lowering alone Plaque Regression Baseline Month 12 with Atorvastatin Lo J et al. Lancet HIV. 2015;2:e52-e63. High risk condition and residual risk: HIV-infected persons KEY RECOMMENDATIONS Clinicians should be aware that HIV-infected patients are at increased risk for ASCVD. Risk is independent of major established risk factors. A fasting lipid panel should be obtained in all newly identified HIV-infected patients. For primary prevention, HIV infection may be counted as an additional risk factor for risk stratification. Statin therapy is first-line therapy for elevated LDL-C and non-hdl-c. Drug-drug interactions must be considered. Atorvastatin, rosuvastatin, and pitavastatin are preferred agents. Randomized Trial to Prevent Vascular Events in HIV: REPRIEVE (A5332) Principal Investigators: Steven Grinspoon, MD Pamela S Douglas, MD Udo Hoffmann, MD, MPH Heather Ribaudo, PhD Time Screening Asymptomatic HIV+ patients with no history of CVD And Consent R (n=7500) Randomization Placebo Pitavastatin 4mg/day Intervention 7 year F/u Mechanistic Study Coronary plaque, vascular inflammation, immune activation (n=800) Mechanistic Primary Endpoint CV Death MI Unstable Angina Stroke Arterial Revasc Clinical Primary Endpoint Individual components of primary endpoint All cause death Incidence/Progression of noncalcified plaque; High-risk plaque Inflammatory, immunological, metabolic biomarkers Secondary Endpoints Predictors All Cause of statin Death effects Statin safety and non AIDS comorbidities: DM, Infections, Cancer Figure 4. Schematic overview of REPRIEVE trial design. Funded by NHLBI and NIAID. Supported by KOWA Pharmaceuticals.

7 ARS Question: Which statement about the metabolic syndrome is accurate? 1. The metabolic syndrome is not applicable to persons with HIV. 2. The metabolic syndrome is correlated with cardiovascular disease risk. 3. The metabolic syndrome predisposes patients to chronic obstructive pulmonary disease. 4. Persons with the metabolic syndrome should be referred to a neurologist for neurocognitive testing. 5. I am currently in a metabolic syndrome because of the delicious desserts that Donna Jacobson provided at lunch. Don t Forget: The ABCDEs of Cardiovascular Disease Management A: Aspirin B: Blood pressure C: Cholesterol D: Diabetes E: Exercise S: Smoking Population Age <50 yrs ASPIRIN Use For Primary Prevention US Preventive Services Task Force Age with 10% CVD risk Age with 10% CVD risk Age >70 yrs Recommendation Insufficient Evidence to Recommend Low Dose ASA for primary CVD prevention Low Dose ASA for primary CVD prevention (Unless bleeding risks prohibit) Insufficient Evidence to Recommend Cross sectional study from UAB 1917 HIV Clinic Only 17% who qualified were prescribed ASA Underutilization of ASA for primary CVD prevention. Burkholder GA. Clin Infect Dis Dec;55(11):

8 How to Beat Inflammation and Prevent CVD Adherence to HIV medications. Stay undetectable Smoking cessation Maintain normal weight If overweight, lose at least 5-10% of body weight Exercise Have a healthy diet Cut down on alcohol, avoid drugs We Mind Very Much If You Smoke Tobacco use decreased in the US population 43% in % in 2010 Remains leading cause of preventable death Contributing to >440,000 deaths annually % of PLWH continue to smoke tobacco Independent risk factor for all cause mortality Koh HK. JAMA. Aug ;308(8): Cockerham L. JAIDS. 2010;53(1): Lifestyle Modification: Diet Cutting 500 calories per day will decrease your weight by 1-2 lbs week Watch portion sizes Watch liquid calories (soda, juice, fruit drinks Go natural Avoid foods in boxes and cans (less salt and preservatives) Maximize fresh fruits and vegetables Effect of Cutting 500 cal/day for 8 wks in Obese HIV neg Persons 4.4 kg weight loss 6.2% weight Significant declines in inflammation CRP IL-6 TNFα Homocysteine Hermsdorff HH. Endocrine Dec;36(3):445-51

9 Lifestyle Modification: Exercise 150 minutes/week of exercise (minimum) Do something you like (combination of cardio/strength) Set a fitness goal (eg 5K race) Find a fitness buddy Unplug Be active during day: If job is sedentary, take breaks to walk Take stairs rather than elevator; park further away to walk to work Exercise Training Reduced Oxidative Stress and Improves Functional Status in HIV 8 week intervention of 24 sessions (aerobic, resistance, or combined) Significant improvements in muscular strength and cardiopulmonary function. Deresz LF. HIV Clin Trials Oct 27:1-6. HIV and CVD Summary HIV and its therapy contribute to cardiac risk along with the traditional host factors Controlling viral replication partially reduces CVD risk. Early ART may significantly mitigate HIV-associated CVD risk. No reliable inflammatory markers to predict risk. Currently available risk scores fail to accurately estimate CVD risk in the setting of HIV infection. Smoking cessation, dietary and exercise interventions are effective. Statins may provide benefit in addition to lipid lowering effects. HOWEVER, more data are needed to inform use in traditional low risk populations.

10 Question-and-Answer

11 Cardiovascular Disease Management in HIV Infection Turner Overton, MD SUGGESTED READINGS Feinstein MJ, Bahiru E, Achenbach C, et al. Patterns of cardiovascular mortality for HIV-infected adults in the United States: 1999 to Am J Cardiol. 2016;117(2): Grinspoon S. Novel mechanisms and anti-inflammatory strategies to reduce cardiovascular risk in human immunodeficiency virus. Trans Am Clin Climatol Assoc. 2018;129: Hsue PY, Waters DD. Time to recognize HIV infection as a major cardiovascular risk factor. Circulation. 2018;138(11): Longenecker CT, Sullivan C, Baker JV. Immune activation and cardiovascular disease in chronic HIV infection. Curr Opin HIV AIDS. 2016;11(2):